Susceptibility testing of bacteria recovered from patients with peritonitis complicating continuous ambulatory peritoneal dialysis.

Antimicrobial Agents and Chemotherapy
H LudlamP Hopkins

Abstract

Antagonism of antibiotic activity by peritoneal dialysate has been postulated to be a cause of failure of treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. We evaluated by a case-control study whether unexpected treatment failure could be attributed to such antagonism. Bacteria isolated from 34 patient episodes of peritonitis treated with the same regimen of ciprofloxacin monotherapy were studied. Ciprofloxacin was significantly less active in dialysate than in Iso-Sensitest broth (IB). The median MIC in IB was 0.5 microgram/ml, increasing to 2.0 micrograms/ml for both fresh dialysate (FD) (P = 0.003) and pooled dialysis effluent (PDE) (P = 0.03); the median MBC in IB was 8.0 micrograms/ml, increasing to 128.0 micrograms/ml in FD (P = 0.0002) and 64.0 micrograms/ml in PDE (P = 0.02). However, no significant differences were found in the results for patients suffering unexpected treatment failure (relapse of peritonitis) compared with the results for patients whose infection resolved without sequel. In IB the median MICs for relapsers and nonrelapsers were 1.0 and 0.5 microgram/ml, respectively (P = 0.88); median MBCs were 32.0 and 4.0 micrograms/ml (P = 0.19). In FD median MICs for relapsers and n...Continue Reading

References

Sep 1, 1977·The Journal of Antimicrobial Chemotherapy·J M Hamilton-Miller
Jun 1, 1976·The Journal of Antimicrobial Chemotherapy·S Selwyn
Sep 1, 1976·The Journal of Antimicrobial Chemotherapy·D Greenwood
Jun 1, 1991·The Journal of Hospital Infection·H A Ludlam
Nov 1, 1990·Antimicrobial Agents and Chemotherapy·H AnwarJ W Costerton
Sep 1, 1990·The Journal of Antimicrobial Chemotherapy·M H Wilcox, R G Finch
May 1, 1990·The Journal of Antimicrobial Chemotherapy·C QuentinC Bebear
Nov 1, 1989·The Journal of Hospital Infection·H A LudlamI Phillips
Jan 1, 1989·Blood Purification·S Lamperi, S Carozzi
Dec 1, 1986·European Journal of Clinical Microbiology·D GuayP Peterson
Sep 1, 1988·Journal of Medical Microbiology·R C Spencer
Sep 1, 1988·Journal of Clinical Microbiology·H A LudlamI Phillips
Apr 1, 1987·Antimicrobial Agents and Chemotherapy·E M McCormick, R M Echols
Jun 1, 1987·Antimicrobial Agents and Chemotherapy·R C Evans, C J Holmes
Jun 1, 1987·European Journal of Clinical Microbiology·C Weissauer-CondonF D Daschner
Jul 1, 1987·The Journal of Antimicrobial Chemotherapy·R EdwardsR G Finch
Mar 1, 1985·The Journal of Antimicrobial Chemotherapy·M H WilcoxR G Finch
Aug 1, 1984·Journal of Clinical Microbiology·H A VerbrughP K Peterson

❮ Previous
Next ❯

Citations

Sep 4, 2013·Biofouling·Margarida MartinsRosário Oliveira
Jan 28, 2005·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·John R HotchkissPhilip S Crooke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.